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OBJECTIVE — The objective of this study was to assess the risk of acute pancreatitis in
patientswithtype2diabetescomparedwiththatinpatientswithoutdiabetes.Wealsoexamined
the risk of biliary disease (deﬁned as occurrence of cholelithiasis, acute cholecystitis, or chole-
cystectomy), which is a major cause of pancreatitis.
RESEARCH DESIGN AND METHODS — We conducted a retrospective cohort study
using a large, geographically diverse U.S. health care claims database. Eligible patients (18
years) were enrolled for at least 12 continuous months (1999–2005), with no incident events of
pancreatitis or biliary disease during that 1 year baseline period. ICD-9 codes and prescription
data were used to identify patients with type 2 diabetes; ICD-9 codes were also used to identify
cases of pancreatitis and biliary disease. Overall, 337,067 patients with type 2 diabetes were
matched on age and sex with 337,067 patients without diabetes. Incidence rates of disease and
95% CI were calculated per 100,000 person-years of exposure.
RESULTS — The type 2 diabetic cohort had a 2.83-fold (95% CI 2.61–3.06) greater risk of
pancreatitis and 1.91-fold (1.84–1.99) greater risk of biliary disease compared with the nondi-
abeticcohort.Relativetopatientsofcorrespondingagewithoutdiabetes,youngertype2diabetic
patients had the highest risk of pancreatitis (45 years: incidence rate ratio [IRR] 5.26 [95% CI
4.31–6.42]; 45 years: 2.44 [2.23–2.66]).
CONCLUSIONS — These data suggest that patients with type 2 diabetes may have an
increased risk of acute pancreatitis and biliary disease.
Diabetes Care 32:834–838, 2009
A
cutepancreatitisisaninﬂammatory
condition of the pancreas. World-
wideannualincidenceofacutepan-
creatitis varies 10-fold, with western
countries reporting an increased inci-
dence over the past 40 years (1). Gall-
stones and alcohol abuse are the most
common causes of acute pancreatitis, ac-
counting for 60–80% of cases (2). The
etiology of acute pancreatitis remains un-
known in 20% of patients (3). Acute
pancreatitis is a risk factor for subsequent
development of recurrent pancreatitis in
4–14% of patients (4).
The reason for the increased inci-
dence of acute pancreatitis is unknown.
However, it is notable that a concurrent
trend has been the rapid, worldwide
increase in type 2 diabetes and obesity.
Several clinical factors associated with
type 2 diabetes (5,6) and obesity (7–11)
are known or putative risk factors for
acute pancreatitis; therefore, it seems
likely that the risk of acute pancreatitis
in patients with type 2 diabetes would
behigherthanthatofthegeneralpopula-
tion. However, the published literature
appears to be largely silent regarding
whether type 2 diabetes is a risk factor
for pancreatitis (7).
Exenatide was approved in April
2005 by the U.S. Food and Drug Admin-
istrationasadjunctivetherapytoimprove
glycemic control in patients with type 2
diabetes.Aftermarketintroduction,there
were spontaneous reports of pancreatitis
that prompted this investigation. Speciﬁ-
cally, the objective of this study was to
assess the risk of acute pancreatitis and
biliary disease in patients with type 2 di-
abetes compared with that in patients
without diabetes.
RESEARCH DESIGN AND
METHODS— A retrospective claims
database analysis was performed using a
proprietary research database containing
eligibility information and pharmacy and
medicalclaimsdatafromalargecommer-
cial U.S. health plan providing coverage
for physician, hospital, and prescription-
drugservices.Theplansubscribersrepre-
sent a geographically diverse sampling
from all regions of the U.S., with the
greatest proportions of members in the
Midwest and South. The database in-
cludes medical and prescription drug
beneﬁt claims data for 14 million pa-
tientsduring2007.Dataderivedfromthis
source have been used for a variety of uti-
lization, safety, and economic analyses
(12–14).
Eligible patients were 18 years and
enrolled for at least 12 continuous
months from 1999 to 2005, with at least
30 days of follow-up from the end of the
1-year enrollment (n  9,249,211). The
index date was deﬁned as the date when
thepatientaccrued1yearofpriorcontin-
uous enrollment (the baseline period).
Table 1 presents the patient selection
process. Patients were assigned to the
nondiabeticcohortifduringthestudype-
riod, they had no medical claims for dia-
betes (ICD-9 code 250.xx), no claim for
an antidiabetic medication, and at least
one medical claim processed (n 
6,947,299). Patients were assigned to the
type 2 diabetic cohort if during the study
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tes (250.x0 or 250.x2) and a ﬁlled pre-
scription for an antidiabetes medication
(n  386,369). Antidiabetes medications
were deﬁned as biguanides, sulfonylureas,
thiazolidinediones, -glucosidase inhibi-
tors, meglitinides, D-phenylalanine deriva-
tives, pramlintide, exenatide, or insulins.
Patientsreceivinginsulin-onlytherapywith
a claim for type 1 diabetes (250.x1 or
250.x3)wereexcludedfromthestudy(n
352,633 patients remaining).
Only patients of known sex were in-
cluded in either cohort. Cohorts were
pair-matched 1:1 on sex and age (n 
352,569). The pairs with available claims
data after matching were used for this
analysis (n  337,067).
Patients with acute pancreatitis (ICD-9
code577.0),cholelithiasis(574.2x,574.5x,
574.9x, 576.1x, and 576.2x), acute chole-
cystitis (574.0x, 574.3x, 574.6x, 574.8x,
575.0, and 575.12), and cholecystectomy
(51.2x) were identiﬁed based on the
presence of the relevant diagnosis code
on any medical claim. To ensure that
this was a study of disease incidence,
patients were excluded if they experi-
encedoutcomeeventsduringthe1-year
baseline period. Speciﬁcally, for the
pancreatitis analysis, patients were ex-
cluded if they had any claimfor acute or
chronic pancreatitis during the 1-year
pre-enrollment period. For the biliary
analysis, patients were excluded if they
had any claim for cholelithiasis, acute
cholecystitis, or cholecystectomy dur-
ing the 1 year pre-enrollment. Labora-
tory, radiology, and pathology claims
were not used to identify outcome
events.
The total time at risk began on the
index date and ended on the date of the
ﬁrst outcome event, disenrollment date,
or the end of study date—whichever oc-
curred ﬁrst. For each cohort, exposure-
adjusted incidence rates (per 100,000
patient-years of exposure) and 95% CI
were calculated using Wald’s method
(15) for the overall cohort, stratiﬁed by
age category and sex. Exposure-adjusted
incidencerateratios(IRRs)andaccompa-
nying 95% CIs between the two groups
and within each stratum were also calcu-
lated (16). Patients with a diagnostic
code for acute pancreatitis, cholelithia-
sis, acute cholecystitis, or cholecystec-
tomy served as the numerators for
the incidence calculations. All patient-
years within each cohort served as the
denominators.
RESULTS— The incidence rate for
pancreatitis in the type 2 diabetic cohort
was 422 cases per 100,000 patient-years
comparedwith149casesper100,000pa-
tient-years in the nondiabetic cohort. In
thediabeticcohort,theincidenceratewas
relatively constant across age-groups in
contrast to the nondiabetic cohort, in
which age was positively correlated with
the incidence of pancreatitis (Table 2).
Overall, the type 2 diabetic cohort
was at 2.83-fold (95% CI 2.61–3.06)
greaterriskofpancreatitiscomparedwith
the nondiabetic cohort. Relative to pa-
tients of corresponding age without dia-
betes, the youngest type 2 diabetes age-
group (18–30 years) had the highest IRR
ofacutepancreatitis(7.75[95%CI3.89–
15.43]),whereaspatientsaged65years
with type 2 diabetes had the lowest IRR
(1.64[1.36–1.98]).Becausetype2diabe-
tes typically occurs in patients aged 45
years, the IRRs of pancreatitis were calcu-
lated among individuals aged older and
younger than 45 years. The results indi-
cated that type 2 diabetic patients be-
tween the ages of 18 and 44 years
experienced a 5.26-fold (95% CI 4.31–
6.42) increased incidence of pancreatitis
and those patients aged 45 years had a
2.44-fold (2.23–2.66) increased inci-
Table 1—Patient selection criteria for a retrospective claims database study of the risk of pancreatitis or biliary disease associated with type
2 diabetes
Patients remaining Patients removed
Enrolled in health plan at any time from 1 January 1999 through 31 December 2005 29,332,477 —
Total population aged 18 years as of 1 January 2000, continuous enrollment for 1 year
from 1 January 1999 through 31 December 2005
12,210,809 17,121,668
At least 30 days of continuous enrollment from the end of 1-year enrollment 9,249,211 2,961,598
Control cohort: patients without diabetes
No medical claims for diabetes (250.xx) during the study period 8,579,024 670,187
No claims for antidiabetes medication during study period 8,521,490 57,534
Sex is unknown 8,519,558 1,932
Any medical claims during the study period 6,947,299 1,572,259
Study cohort: type 2 diabetes
Claim for type 2 diabetes or antidiabetic medication at any time from 1 January 1999
through 31 December 2005
1,337,081 —
Claim for type 2 diabetes or antidiabetes medication during the continuous enrollment
period
640,504 696,577
Medical claim for type 2 diabetes (250.x0 or 250.x2) during the continuous enrollment
period
563,827 76,677
Claim for antidiabetes medication during the continuous enrollment period 463,046 100,781
Medical claim for type 2 diabetes (250.x0 or 250.x2) AND a claim for an antidiabetes
medication during 1 January 1999 through 31 December 2005
386,369 76,677
Drop patients on insulin-only therapy AND claim for type 1 diabetes (250.x1 or 250.x3) 352,633 33,736
Sex is known 352,569 64
Matching
Pairs matched 1:1 by sex and age category 352,569 —
Pairs with available claims data 337,067 15,502
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nondiabetic counterparts of the corre-
sponding age-group. For acute pancreati-
tis, the IRRs were similar between males
and females in the two cohorts.
The incidence rate for biliary disease
in the type 2 diabetic cohort was 1,411
cases per 100,000 patient-years com-
pared with 737 cases per 100,000 pa-
tient-years in the nondiabetic cohort. In
thediabeticcohort,theincidenceratewas
highest in the youngest (18–30 years)
and oldest (65 years) age-groups, in
contrast to the nondiabetic cohort in
which age was positively correlated with
the incidence of pancreatitis (Table 3). In
both cohorts, the incidence of biliary dis-
easewasnotablyhigherinwomenthanin
men, although the IRRs were similar be-
tween the sexes for the two cohorts.
Overall, the type 2 diabetic cohort
had a 1.91-fold (95% CI 1.84–1.99)
greater risk of biliary disease than the
nondiabeticcohort.Relativetopatientsof
corresponding age without diabetes, the
youngest type 2 diabetes age-group
(18–30 years) had the highest IRR of bil-
iary disease (3.77 [95% CI 2.92–4.87]),
whereas patients aged 65 years with
type 2 diabetes had the lowest IRR (1.50
[1.37–1.65]).
Examination of the biliary disease
subgroups revealed that cholelithiasis
contributed 50% of the total incident
cases of cholecystitis, cholecystectomy,
and cholelithiasis among both cohorts,
and the incidence of cholelithiasis in type
2 diabetic patients was considerably
higher (1,229 cases per 100,000 patient-
years)thanthatinpatientswithoutdiabe-
tes (647 cases per 100,000 patient-years)
(data not shown).
CONCLUSIONS — This study sug-
gests that patients with type 2 diabetes
have an almost threefold greater risk of
pancreatitis and twofold greater risk of
biliary disease than patients without dia-
betes.Thehighriskofpancreatitisamong
younger patients with type 2 diabetes
relative to their nondiabetic peers is par-
ticularly notable, although the clinical
meaning of this ﬁnding needs to be
elucidated.
This study was limited by the data
available in a managed care claims data-
base, given that claims data are collected
for payment and not for research. Patient
compliance with prescription medica-
tions and use of physician samples were
not captured. In addition, data regarding
other possible risk factors for pancreatitis
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and concomitant medications) were not
available. Another potential limitation is
error in disease ascertainment, given that
diagnostic codes may be incorrectly
coded or included as rule-out criteria
rather than actual disease. For example,
although we used a conservative algo-
rithm for identifying patients with type 2
diabetes (ICD-9 code AND use of an an-
tidiabetic agent), some patients with type
1 diabetes were probably included in the
cohorts, particularly in the younger age-
groups. It is also noteworthy that the in-
cidence rate of pancreatitis for the
nondiabeticcohortreportedinthisepide-
miologicstudyisapproximatelythreefold
greater than published estimates for the
generalpopulation(1,4).Thehigherinci-
dence of pancreatitis found in this study
may be representative of an increase in
pancreatitis,claimsmiscodingforpancre-
atitis, population differences, or the re-
porting method. A study of the accuracy
ofICD-9codesforpancreatitisconducted
in a large VA population reported excel-
lent sensitivity (93%) but lower speciﬁc-
ity (79%) for acute pancreatitis (17);
hence, it is likely that false-positive re-
ports of pancreatitis were included in this
study. Although the reason for the higher
incidence of pancreatitis observed in this
study is unknown, it is likely to be non-
differential across the two cohorts such
that the increased risk of pancreatitis ob-
served among the patients with type 2 di-
abetes is valid.
Strengths of this study include the
large sample size, which is necessary
given that pancreatitis is a rare event.
These data also allow for the examination
of health outcomes in a “real world” set-
ting including a nationwide sample of pa-
tients with diverse medical histories.
Nonetheless, the data used for this study
come from a managed care population,
and results are applicable primarily to the
prevalence of outcomes in managed care
settings. Age and sex bias were controlled
forbypairmatching.Finally,theseresults
areprobablyconservative,giventhatsub-
jectswithundiagnoseddiabetesmayhave
been included in the nondiabetic cohort,
a problem that is not unique to claims
data.
In summary, the nearly threefold in-
creased risk of pancreatitis for patients
with type 2 diabetes reported here, com-
bined with the increasing prevalence of
diabetes and the associated risk factors,
may be contributing to a meaningful in-
creaseintheincidenceofacutepancreati-
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causal factors that may account for the
observed increased risk of pancreatitis as-
sociated with diabetes.
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